{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042086","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.376148+00:00","generated_at":"2026-06-11T12:21:10.958575+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MindMed enters up to $50M term loan with K2 HealthVentures; first tranche of $15M funded","bullets":["Loan Agreement with K2 HealthVentures provides term loans up to $50M; initial $15M drawn on Aug 11, 2023.","Additional $20M available upon clinical/regulatory milestones; up to $15M more at lenders' discretion.","Term loan matures Aug 1, 2027; interest rate = greater of 10.95% or Prime + 2.95%.","Lenders may convert up to $4M of principal into common shares at $4.01 per share; conversion capped at 9.985% beneficial ownership.","Proceeds for working capital and general corporate purposes; loan secured by substantially all assets except IP."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042086","json":"https://secwatch.observer/filing/0000950170-23-042086.json","markdown":"https://secwatch.observer/filing/0000950170-23-042086.md","text":"https://secwatch.observer/filing/0000950170-23-042086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023042086/0000950170-23-042086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023042086/mnmd-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:21:10.958575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f98819d0bc05ed5742f3adf546bef95fb158f044","claim":"Definium Therapeutics, Inc. entered into Loan and Security Agreement with K2 HealthVentures LLC, as administrative agent and Canadian collateral agent, and the lenders referred to therein valued at $50.0 million in term loans (effective 2023-08-11).","evidence_excerpt":"On August 11, 2023 (the “Closing Date”), Mind Medicine (MindMed) Inc. (the “Company”) and certain of its subsidiaries party thereto, as co-borrowers (together with the Company, the “Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with the lenders referred to therein (the “Lenders”), K2 HealthVentures LLC (“K2HV”), as administrative agent and Canadian collateral agent for the Lenders, and Ankura Trust Company, LLC, as collateral trustee for the Lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023042086/0000950170-23-042086-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"K2 HealthVentures LLC, as administrative agent and Canadian collateral agent, and the lenders referred to therein"},{"label":"Value","value":"$50.0 million in term loans"},{"label":"Effective","value":"2023-08-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}